Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosis

Murray, T. Jock
September 2003
ACP Journal Club;Sep/Oct2003, Vol. 139 Issue 2, p45
Academic Journal
Presents a study that investigated the effectiveness of mitoxantrone in slowing progression of disability and reducing relapses in patients with multiple sclerosis. Design; Intervention; Outcome measures; Results; Commentary.


Related Articles

  • Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. Sadiq, Saud A.; Rammal, Mustapha; Sara, Gabriel // Multiple Sclerosis (13524585);Mar2008, Vol. 14 Issue 2, p272 

    We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone...

  • Mitoxantrone.  // Reactions Weekly;11/24/2007, Issue 1179, p25 

    The article describes the case of two patients who, after receiving mitoxantrone for multiple sclerosis, developed acute myeloid leukaemia. A 53-year-old woman, over a period of about 17 months, received eight infusions of mitoxantrone 20mg. She developed acute myeloid leukaemia of the M3...

  • Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis. Zaffaroni, Mauro; Rizzo, Annalisa; Baldini, Silvana; Ghezzi, Angelo; Comi, Giancarlo // Neurological Sciences;Sep2008 Supplement 2, Vol. 29, p230 

    We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/ persistently active...

  • Mitoxantrone helps decrease pain of PCa.  // Urology Times;Oct96, Vol. 24 Issue 10, p40 

    Reports that the US Food and Drug Administration has recommended for approval mitoxantrone from Immunex for use in hormone-resistant prostate cancer.

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS33 

    Presents an abstract of the research manuscript `Response-adapted treatment of de novo acute myeloblastic leukemia (AML): Update of a phase II multi-center study of sequential induction regimens idarubicin/cytarabine and mitoxantrone/etoposide,' by R. van der Jagt, S. Robinson et al from the...

  • Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity. Shenkenberg, Todd D.; Von Hoff, Daniel D. // Annals of Internal Medicine;Jul86, Vol. 105 Issue 1, p67 

    Focuses on the clinical usefulness of mitoxantrone in the treatment of cancer. Biochemistry and general biologic effects of the drug; Mechanism of action; Mechanism of resistance; Animal toxicology; Antitumor activity of mitoxantrone against various experimental mouse tumors.

  • Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Johnson, KP; Brooks, BR; Ford, CC; Goodman, AD; Lisak, RP; Myers, LW; Pruitt, AA; Rizzo, MA; Rose, JW; Weiner, LP; Wolinsky, JS // Multiple Sclerosis (13524585);Dec2003, Vol. 9 Issue 6, p585 

    The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active treatment versus those on placebo for approximately 30 months (24-35 months) before receiving GA during a six-year organized, prospective...

  • Advanced PCa agent prolongs progression-free survival. Gebhart, Fred // Urology Times;May2011, Vol. 39 Issue 5, p10 

    The article presents information on the phase III prostate cancer clinical trial where the effective use of cabazitaxel noticed 30 percent improvement in survival men of metastatic castration-resistant prostate cancer. Doctor Oliver Sartor reports on the effective use of docetaxel (Taxotere) in...

  • Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. Barbosa Pagnano, Kátia B.; de Carvalho Duarte, Gustavo; Lorand-Metze, Irene; Delamain, Márcia Torresan; Miranda, Eliana Cristina; de Souza, Cármino Antonio // Advances in Hematology;2010, Vol. 2010, p1 

    We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics